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Abstract
Background: To investigate the individual sequential hemodynamic changes after transcatheter aortic 
valve implantation (TAVI), especially for patients with bicuspid aortic valve (BAV), in comparison with 
tricuspid aortic valve (TAV).
Methods: The study population comprised 85 patients with severe aortic stenosis who underwent 
TAVI for BAV (n = 49) or TAV (n = 36) with at least two serial echocardiographic follow-ups. Doppler 
echocardiography was scheduled to be performed at discharge and 1, 3, 6 months and 1 year after the 
procedure. D peak transvalvular velocities and D mean transvalvular gradients were calculated as the 
difference at follow-up time points and discharge. Paravalvular leak (PVL) was assessed as another 
indicator for prosthesis performance.
Results: Comparisons between patients with BAV and TAV revealed similar gradient performances 
(1.00 [–2.00, 2.00] vs. 1.00 [–0.25, 5.00] mm Hg, p = 0.57 at 1 month; –0.71 ± 7.52 vs. 1.55 ± 3.97 
mm Hg, p = 0.21 at 3 months; 0.96 ± 7.81 vs. 1.53 ± 5.85 mm Hg, p = 0.79 at 6 months; 1.00 [–0.50, 
2.25] vs. 3.00 [–0.50, 7.50] mm Hg, p = 0.07 at 1 year). Moreover, the incidence of ≥ mild PVL was not 
significantly different in patients with BAV and TAV during follow-up (34.88% vs. 19.35%, p = 0.14  
at 1 month; 45.83% vs. 27.27%, p = 0.19 at 3 months; 30.00% vs. 23.53%, p = 0.89 at 6 months; 
30.00% vs. 17.65%, p = 0.56 at 1 year).
Conclusions: TAVI is effective and applicable in BAV anatomy with sustained and acceptable mid- 
-term prosthesis hemodynamic performance. (Cardiol J 2017; 24, 4: 350–357)
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Introduction
During the past decade, transcatheter aortic 
valve implantation (TAVI) has evolved rapidly as an 
alternative treatment option to conventional aortic 
valve replacement (AVR) for those who are deemed 
inoperable or at high risk for surgery. The safety 
and effectiveness of this new technique has been 
demonstrated, as well as sustained transvalvular 
hemodynamics post-TAVI has also shown signifi-
cant improvement in symptoms [1, 2]. Despite data 
favoring low transprosthetic gradients and large 
prosthetic valve effective orifice area in several 
studies [3–6], the assumption that implantation 
of a percutaneous bioprosthesis within the native 
valve might lead to incomplete expansion of the 
prosthetic valve [7] is still worrisome, since the 
evidence in individual continuous hemodynamic 
change has been lacking. This is especially true 
in bicuspid aortic valve (BAV) patients for their 
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pre-existing abnormal cusp fusion, heavily calci-
fied leaflets and possible raphe, all of which, could 
theoretically jeopardize the prosthetic valve func-
tion [8]. 
Transvalvular gradients on Doppler echocar-
diography has been shown to correlate well with 
invasive measures for assessing valve function 
and hemodynamics after AVR [9]. In this study, we 
sought to use mid-term serial echocardiographic 
follow-up data to identify the changes of these two 
hemodynamic parameters and to compare the dif-
ferences between BAV patients and their tricuspid 
counterparts.
Methods
Data from patients with severe symptomatic 
aortic stenosis who underwent TAVI in our center 
with at least two serial echocardiographic follow-
ups were retrospectively collected into two groups 
according to valve morphology. BAV patients were 
not denied for TAVI at our center. The definition 
and classifications of BAV have been described 
elsewhere [8]. It is characterized as the abnormal 
aortic valve morphology consisting of two func-
tional cusps with less than three zones of parallel 
apposition between cusps. The number and spatial 
orientation of the raphe were used to classify this 
morphology. Possible BAV patients were identified 
on echocardiography, but measurements of the 
aortic annulus, diagnosis and classification of BAV 
were confirmed by interpreting pre-procedural 
multi-slice computed tomography (MSCT) with 
commercially available software, OsiriX (OsiriX 
Foundation, Geneva, Switzerland), by methods 
proposed earlier [10]. All patients were evaluated 
by a multidisciplinary team beforehand. If the 
diagnosis of severe aortic stenosis was confirmed 
on echocardiography and considered by cardiac 
surgeons to be inoperable or at high surgical risk, 
TAVI was considered. The study protocol was ap-
proved by the institutional review board and all 
patients provided written, signed consent.
MSCT was routinely performed to evaluate 
the anatomical suitability for TAVI and guide the 
selection of access route and prosthesis size. TAVI 
was performed with self-expanding systems, the 
first-generation CoreValve (Medtronic, Minne-
apolis, Minnesota) or the Venus A-Valve (Venus 
MedTech Inc., Hangzhou, China). The decision 
for using one of the two valves depended on valve 
availability. The Venus A-Valve is a self-expanding 
nitinol stent frame carrying a trileaflet porcine 
bioprosthetic valve. The delivery system is 18-Fr 
and can be delivered sheathless by the transfemoral 
as well as transaxillary/transsubclavian approach, 
and with a sheath for the transaortic approach. 
The radial force of expansion for the inflow was 
increased, enabling a more consistent device ex-
pansion in the presence of extreme aortic valve 
calcification [11]. All procedures were performed 
in the hybrid operating room with patients under 
general anesthesia. Intraprocedural transesopha-
geal echocardiography (TEE) was performed to 
assess the performance of the prosthetic valve in 
the absence of contraindication. The transfemoral 
approach was the defaulted access, and if it was 
not feasible, the transsubclavian approach was 
considered as the alternative. Procedural details 
of TAVI with the self-expanding devices have been 
described previously [12, 13]. 
Doppler echocardiography was systematically 
performed at baseline and at hospital discharge in all 
patients. The timing of echocardiographic exams at 
follow-up was set at 1 months, 3 months, 6 months 
and 1 year after procedure and then yearly. Left 
ventricular ejection fraction (LVEF), stroke volume 
(SV), transvalvular gradients and peak velocity 
were measured following the methods previously 
described [14]. D peak transvalvular velocities were 
calculated as the difference at the four follow-up 
intervals and discharge if available. Results were 
shown as DV1 for peak velocity at discharge sub-
tracted the value at 1 month after procedure, DV2, 
DV3, DV4 and so on. Likewise, D mean transvalvular 
gradient was calculated as the difference at the four 
follow-up intervals and discharge if available. Re-
sults were shown as DG1 for mean transvalvular gra-
dient at discharge subtracted the value at 1 month 
after procedure, DG2, DG3, DG4 and so on. Prosthetic 
valve function and paravalvular leak (PVL) were also 
assessed as an indicator for prosthesis performance 
in accordance to the updated Valve Academic Re-
search Consortium (VARC) criteria [15] and shown 
as none (0), trace (1) and mild or more than mild 
(≥ 2) in this study.
Statistical analysis
Continuous variables are reported as mean 
± standard deviation or median (interquartile 
range). Categorical variables were presented 
as frequencies and percentages. Differences in 
proportions were assessed using the c2 test or 
Fisher’s exact test. To test for differences in means 
between groups with continuous variables, an 
unpaired Student’s t test (one-way ANOVA was 
used if the comparison was among more than two 
groups) or Mann-Whitney or Kruskal–Wallis-H 
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non-parametric test was used. To test if two vari-
ables vary together, simple scatter plot was used 
to see whether potential correlation existed, and 
if so, Pearson correlation calculations or Spearman 
nonparametric correlation would be utilized for the 
correlation coefficient. All computations relied on 
commercially available software (SPSS IBMS v. 21 
for Mac; SPPS Inc., Chicago, IL, USA), with statis-
tical significance set at two-tailed 0.05.
Results
A total of 85 patients were identified. The 
mean age was 74.00 years and 50 (58.82%) patients 
were male. A total of 57.65% (49/85) of patients 
were with BAV (30 with type 0; 19 with type 1 
including 14 left-right, 4 right-non and 1 left-non), 
which was in line with a previously reported co-
hort [16]. The mean Society of Thoracic Surgeons 
Predicted Risk of Mortality (STS-PROM) score 
was 7.38 ± 0.42%. Nearly all patients (97.65%) 
underwent TAVI with the transfemoral approach. 
A total of 47.06% (40/85) of patients received the 
Medtronic CoreValve, while the others received 
the Venus A-valve. The demographic and proce-
dural characteristics of the study population are 
summarized in different valve morphologies in 
Table 1. At the time of data retrieval, there were 
80 patients with transthoracic echocardiography 
(TTE) at discharge. The numbers of available 
TTE follow-ups were 74, 46, 47 and 47 at 1 month, 
3 months, 6 months and 1 year after the procedure, 
respectively. 
DV1 = 0.005 (–0.138, 0.200) m/s, DV2 = 0.000 
(–0.190, 0.290) m/s, DV3 = 0.055 (–0.300, 0.338) m/s, 
DV4 = 0.200 (–0.100, 0.340) m/s with no significant 
differences among them (p = 0.53). At the same 
follow-up period, no significant differences were 
detected between BAV and tricuspid aortic valve 
(TAV) patients for DV at 1 month (0.000 [–0.185, 
0.198] vs. 0.040 [–0.090, 0.300] m/s, p = 0.35); 
at 3 months (0.000 [–0.308, 0.300] vs. 0.000 [–0.130, 
0.235] m/s, p = 0.75); and at 6 months (0.100 
[–0.300, 0.400] vs. –0.020 [–0.400, 0.313] m/s, 
p = 0.67), except for 1-year follow-up (0.03 [–0.180, 
0.300] vs. 0.275 [0.070, 0.530] m/s, p = 0.04). 
On the other hand, DG1 = 1.00 (–0.50, 3.00) mm 
Hg, DG2 = 1.00 (–2.25, 3.00) mm Hg, DG3 = 1.00 
(–2.00, 5.00) mm Hg, DG4 = 2.00 (0.00, 3.00) mm Hg 
with no significant differences among them 
(p = 0.79). Also, differences between BAV and TAV 
patients for DG did not reach statistical significance 
at all follow-up intervals: at 1 month (1.00 [–2.00, 
2.00] vs. 1.00 [–0.25, 5.00] mm Hg, p = 0.57); at 
3 months, –0.71 ± 7.52 vs. 1.55 ± 3.97 mm Hg, 
p = 0.21; at 6 months, 0.96 ± 7.81 vs. 1.53 ± 5.85 
mm Hg, p = 0.79; and at 1 year (1.00 [–0.50, 2.25] 
vs. 3.00 [–0.50, 7.50] mm Hg, p = 0.07). These data 
were illustrated in Figures 1 and 2.
As for PVL, grade ≥ 2 PVL was recorded in 
34.1% (29/85) of patients on TEE after the proce-
dure (38.8% in BAV and 27.8% in TAV, p = 0.29). 
This result was achieved with post-dilation and the 
valve-in-valve procedure. Total of 44.9% (22/49) 
BAV patients underwent post-dilation, while it 
was 41.7% (15/36) in TAV (p = 0.29). Two (5.6%) 
TAV patients underwent valve-in-valve procedure, 
there were 7 (14.3%) patients in BAV (p = 0.29). 
No differences in the distribution of PVL severity 
was seen from the time of discharge (patients with 
grade ≥ 2 PVL in TAV and BAV groups: 33.33% vs. 
31.82%, p = 0.89 at discharge; 19.35% vs. 34.88%, 
p = 0.14 at 1 month; 27.27% vs. 45.83%, p = 0.19 
at 3 months; 23.53% vs. 30.00%, p = 0.89 at 
6 months; 17.65% vs. 30.00%, p = 0.56 at 1 year). 
See Figure 3 for details.
Scatter plots for LVEF or SV and peak veloci-
ties in order to detect possible correlations on all 
four follow-up intervals were drawn (figures not 
shown) with only low correlations between peak 
velocity and SV at discharge and 1-year follow-up 
reaching significance (r = 0.261, p = 0.02 and 
r = 0.403, p < 0.01 respectively).
Discussion
The main findings of this study are that: 
1) Sustained hemodynamic changes are observed 
as peak velocity and transvalvular gradient dif-
ferences between discharge and follow-up within 
1 year after the procedure; 2) BAV does not seem 
to alter hemodynamic changes comparing with its 
TAV counterparts in TAVI with the self-expanding 
transcatheter heart valve (THV); 3) The incidence 
of ≥ grade 2 PVL was not significantly different in 
BAV patients during follow-up.
Unlike AVR, some studies suggested TAVI 
results in immediate and sustained relief in pres-
sure overload and improved left ventricular systolic 
function, with continued regression of hypertrophy 
over time [1]. However, most previous studies have 
only reported the hemodynamic performance at 
each interval without clearly showing the hemody-
namic changes for individual patients between two 
follow-up intervals. As a continuous process, the 
interactions between native valve, aortic annulus 
and surrounding structures, THV and its impact 
on hemodynamics need to be further delineated.
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Because of its asymmetric annulus anatomy, 
BAV is traditionally regarded as a relative contra-
diction for TAVI for the assumption that this chal-
lenging anatomy could exert an increased risk of 
uneven expansion of THV and may lead to leaflet 
deformity and PVL. Zegdi et al. [7] described 
a non-circular stent shape in 85% of patients with 
BAV whereas it was 32% in TAV patients in a study 
where they put non-commercial self-expanding 
stent in 16 patients with BAV and 19 patients 
with TAV before AVR. This proposed elliptical 
shape was later observed in several studies on 
Table 1. Clinical characteristics of the study population and procedure data.
Parameters BAV (n = 49) TAV (n = 36) P
Age [years] 72.65 ± 6.68 73.28 ± 7.42 0.30
Male 31 (63.3%) 19 (52.8%) 0.33
Weight [kg] 57.84 ± 9.84 56.76 ± 10.26 0.70
Height [m] 1.60 ± 0.09 1.61 ± 0.10 0.20
STS score [%] 6.01 (4.39, 9.23) 8.28 (4.89, 9.25) 0.34
NYHA III–IV 44 (89.8%) 32 (88.9%) 0.99
Antecedents
Myocardial infarction 2 (4.1%) 1 (2.8%) 0.99
Prior PCI 3 (6.1%) 2 (5.6%) 0.99
Atrial fibrillation 10 (20.4%) 5 (13.9%) 0.44
Comorbidity
Hypertension 22 (44.9%) 19 (52.8%) 0.47
Diabetes 13 (26.5%) 9 (25.0%) 0.87
Chronic lung disease 28 (57.1%) 27 (75.0%) 0.09
Coronary artery disease 15 (30.6%) 14 (38.9%) 0.43
Peripheral vascular disease 19 (38.8%) 11 (30.6%) 0.43
Chronic kidney disease 6 (12.2%) 6 (16.7%) 0.56
Pre-procedural TEE
Left ventricular function*
Normal 33 (67.3%) 29 (80.6%) 0.18
Moderate 14 (28.6%) 5 (13.9%) 0.11
Impaired 2 (4.1%) 2 (5.6%) 0.99
Peak velocity
Pre-procedure [m/s] 5.10 (4.55, 5.75) 4.90 (4.31, 5.20) 0.05
Post-procedure [m/s] 2.40 (2.00, 2.80) 2.48 (2.12, 2.80) 0.92
Annulus on CT
Maximal diameter [mm] 27.53 ± 3.43 27.13 ± 3.36 0.59
Minimal diameter [mm] 21.88 ± 2.92 20.51 ± 2.54 0.03
Eccentricity index [%]# 20.15 ± 8.91 24.18 ± 6.05 0.02
Procedure
CoreValve 25 (51.0%) 15 (41.7%) 0.58
Valve size
23 mm 1 (2.1%) 1 (2.8%) 0.99
26 mm 22 (44.9%) 15 (41.7%) 0.77
29 mm 15 (30.6%) 13 (36.1%) 0.59
31/32 mm 11 (22.4%) 7 (19.4%) 0.74
*Left ventricular function was determined by visual assessment on transesophageal echocardiography (TEE) and classified as normal in case 
of an estimated ejection fraction of > 50%, moderate if 30% to 50%, and impaired if < 30%; #Eccentricity index = (1 – Dmin/Dmax) × 100;  
BAV — bicuspid aortic valve; CT — computed tomography; TAV — tricuspid aortic valve; NYHA — New York Heart Association;  
PCI — percutaneous coronary intervention; STS — Society of Thoracic Surgeons
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Figure 1. Scatter plots for individual differences in peak velocities at four follow-up time points grouped by valve mor-
phology. Each circle (for bicuspid aortic valve [BAV]) or square (for tricuspid aortic valve [TAV]) in this figure stands 
for the difference in peak velocity between follow-up at that time and at discharge, intentionally arranged by two 
morphology groups for readers to appreciate variations from different anatomical features. NS in the figure represents 
non-significant p value in the student t test or Mann-Whitney test; A. DV1; B. DV2; C. DV3; D. DV4.
Figure 2. Scatter plots for individual differences in mean transvalvular gradients at four follow-up time points grouped 
by valve morphology. Each circle (for bicuspid aortic valve [BAV]) or square (for tricuspid aortic valve [TAV]) in this 
figure stands for the difference in transvalvular gradient between follow-up at that time and at discharge, intentionally 
arranged by two morphology groups for readers to appreciate variations from different anatomical features. NS in 
the figure represents non-significant p value in the student t test or Mann-Whitney test; A. DG1; B. DG2; C. DG3; D. DG4.
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MSCT. Of note, in our reported cohort of patients, 
57.65% were with BAV, which was in line with 
a previous core lab observation [11]. There could 
be two main reasons for the high proportion of BAV 
patients in Chinese TAVI population. The first is 
genetic variances, which still lacks solid evidence 
since different proportions of BAV patients exist 
from center to center [17]. The other explanation 
is related to patient preference. We see more 
frequently younger patients of high surgical risk 
requested TAVI which certainly contributes to this 
phenomenon. However, no significant difference 
was found in the proportion of TAV and BAV using 
D peak velocity on TTE between different time 
intervals after procedure. This finding, together 
with similar mid-term post-procedural hemody-
namic and clinical outcomes with TAV group in 
other studies [18, 19], indicates the presence of 
asymmetric bulky calcification, larger annulus 
size and possible raphes in BAV patients might 
not impair THV function. Of note, the number of 
available TTE follow-ups was small and decreased 
over time. This was mainly due to the absence of 
certain follow-up intervals and the fact that some 
patients did not reach longer follow-up at the 
time of data retrieval. It is noteworthy that in this 
study, the self-expanding valve was the only device 
available at that time. It has been shown in several 
studies that self-expanding CoreValve prosthesis is 
associated with a lower residual gradient and great-
er valve area than balloon-expandable Edwards 
SAPIEN prosthesis [20]. This superior antegrade 
hemodynamic performance could be explained 
by it being at supra-annular position, thus, it may 
exert a lower resistance towards left ventricular 
outflow [20]. Moreover, the longer inflow tract may 
help impose a lower flow contraction to the valve 
anatomic orifice. These factors altogether may have 
contributed to our results. 
Another major concern for BAV patients was 
the risk of PVL, especially with the first-generation 
THV device. Moderate-to-severe PVL after TAVI 
has been found to impair outcomes [21, 22]. The 
presence of raphes, calcifications and difficulties 
in accurate positioning of the THV contribute to 
the risk of PVL in BAV patients. Although the in-
cidence of PVL differed across studies with BAV 
patients, the occurrence of PVL grade ≥ 2 was gen-
erally higher than TAV patients [8, 23, 24]. Similar 
results were found in our reported cohort. Even 
though no significant differences were observed 
in the distribution of PVL severity between BAV 
and TAV patients, it is possible that the lack of 
echocardiography data due to incomplete follow-up, 
which could have affected results. Thus, the high 
incidence of PVL in BAV patients is still concerning 
and requires longer follow-up to detect its clinical 
implications. However, advances in devices allow 
us to address this complication in BAV patients. 
Perlman et al. [25] recently reported no more than 
mild PVL in a cohort of BAV patients treated with 
the SAPIEN 3 valve at 1 month after the procedure. 
Figure 3. Evolution of paravalvular leak (PVL); BAV — bicuspid aortic valve; TAV — tricuspid aortic valve.
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In addition, appropriate computed tomography an-
nular sizing and oversizing strategies are essential 
in reducing the frequency of PVL or central aortic 
regurgitation after TAVI [8]. 
Limitations of the study
Certain limitations do exist. This is a small, 
single-center, observational cohort, in which only 
first-generation self-expanding valves were used. 
The criteria for at least two serial echocardiograph-
ic follow-ups could have decreased the sample size 
due to incomplete follow-up. Although SV or LVEF 
were not found to be correlated with gradients or 
velocities, hemodynamics measured by echocardi-
ography are still easily affected by patient overall 
functional status at follow-up, which should be 
taken into consideration when interpreting these 
results. Moreover, the use of Venus A-valve, which 
is now the only available type in China, could also 
limit the value of this study.
Conclusions
Sustained hemodynamic changes in individual 
peak velocity and transvalvular gradient differ-
ences were observed for 1 year. In this cohort, 
BAV does not seem to alter hemodynamic changes 
when compared with its TAV counterparts after 
TAVI with the self-expanding THV. 
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